High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome

ABSTRACT

Natural killer (NK) cells are major anti-leukemic immune effectors. Leukemic blasts have a negative impact on NK cell function and promote the emergence of phenotypically and functionally impaired NK cells. In the present work, we highlight an accumulation of CD56^-CD16⁺ unconventional NK cells in acute myeloid leukemia (AML), an aberrant subset initially described as being elevated in patients chronically infected with HIV-1. Deep phenotyping of NK cells was performed using peripheral blood from patients with newly-diagnosed AML (N=48, HEMATOBIO cohort, NCT02320656) and healthy subjects (N=18) by mass cytometry. We evidenced a moderate to drastic accumulation of CD56^- CD16⁺ unconventional NK cells in 27% of patients. These NK cells displayed decreased expression of NKG2A as well as the triggering receptors NKp30, and NKp46, in line with previous observations in HIV-infected patients. High-dimensional characterization of these NK cells highlighted a decreased expression of three additional major triggering receptors required for NK cell activation, NKG2D, DNAM-1, and CD96. A high proportion of CD56^-CD16⁺ NK cells at diagnosis was associated with an adverse clinical outcome, with decreased overall survival (HR=0.13; P=.0002) and event-free survival (HR=0.33; P=.018), and retained statistical significance in multivariate analysis. Pseudo-time analysis of the NK cell compartment highlighted a disruption of the maturation process, with a bifurcation from conventional NK cells toward CD56^-CD16⁺ NK cells. Overall, our data suggest that the accumulation of CD56^-CD16⁺ NK cells may be the consequence of immune escape from innate immunity during AML progression.

Significance This work provides the first report of accumulation of unconventional CD56-CD16+ NK cells in non-virally induced malignancies. Pseudotime analysis highlights a bifurcation point occurring during the course of NK cell maturation, providing elements regarding the possible origin of CD56-CD16+ NK cells. Increased frequency of CD56-CD16+ NK cells is associated with adverse clinical outcome in AML and might contribute, as well as other maturation defects, to a defective control of AML progression. Overall, accumulation of CD56-CD16+ NK cells could be an important feature of immune escape from innate immunity.

• Download figure
• Open in new tab

Key points

• A disruption in the maturation process of NK cells leads to accumulation of unconventional CD56^- CD16⁺ NK cells in patients with AML

• High frequency of CD56^-CD16⁺ NK cells is associated with adverse clinical outcome

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work has been financially supported by the INCa (grant 2012-064/2019-038 for D.O., and A.T.), the Fondation de France (grant 00076207 for A.S.C), the SIRIC Marseille (grant INCa-DGOS-INSERM 6038), the Canceropole PACA (grants K_CyTOF 2014 and AML_CyTOF 2016 for J.A.N.), the GS IBiSA and the Agence Nationale de la Recherche (PHENOMIN project for M.M., H.L., and E.G.). The team Immunity and Cancer was labeled Equipe FRM DEQ 201 40329534 (for D.O.)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The entire research procedure was approved by the institutional review board of the Paoli-Calmettes Institute. Handling, conditioning, and storage of samples were performed by the Paoli-Calmettes Tumor bank, which operates under authorization # AC-2007-33 granted by the French Ministry of Research.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes